ResMed stock fell 1.02 percent on October 2 before earnings

Published on 10/04/2026 at 21:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed stock fell 1.02 percent to USD 218.90 on October 2, 2026, before its October 29 results date. Fiscal Q4 revenue rose 8.6 percent to USD 1.46 billion.

Isometrische 3D-Illustration von Labor, Fertigungslinie und Versand medizinischer Geräte — ResMed Inc. (ISIN US7611521078): isometrische 3D-Darstellung zeigt die komplette Wertschöpfungskette von Atemtherapiegeräten und Versand, Illustration mit AI erstellt.

ResMed Inc. (ISIN US7611521078) closed at USD 218.90 on the NYSE on October 2, 2026, down 1.02 percent from USD 221.15. The next scheduled catalyst is the company’s fiscal first-quarter 2027 report on October 29, 2026, after the New York Stock Exchange closes, according to GlobeNewswire.

Revenue growth meets the next test

ResMed’s latest reported quarter ended June 2026. Adjusted earnings reached USD 2.95 per share, versus a Zacks consensus estimate of USD 2.90, while revenue came to USD 1.46 billion, up from USD 1.35 billion a year earlier, according to Zacks.

The comparison gives the stock a mixed operating signal: revenue advanced 8.6 percent year over year, but the quarterly result still leaves investors measuring demand growth against profitability and the next earnings outlook. The USD 0.05 adjusted EPS gap over consensus was positive, while the June-quarter revenue figure establishes the base for the October report.

Analysts see value above the market

MarketBeat records a Hold consensus across 16 covering firms, with nine Hold ratings and seven Buy ratings. The average 12-month price target is USD 241.69, placing it 10.4 percent above the October 2 closing price of USD 218.90, according to MarketBeat.

The target spread shows why the consensus label matters. Recent published targets range from USD 225 to USD 267, while Royal Bank of Canada upgraded ResMed from Sector Perform to Outperform and raised its target from USD 244 to USD 262 on September 15, 2026, as reported by MarketBeat. Competitive pressure remains part of the debate, with Stifel maintaining a Hold rating and a USD 235 target on October 2, 2026, citing possible market share pressure from a competitor’s return, according to Investing.com.

ResMed stock heads toward October results

ResMed had a market capitalization of USD 31.6 billion and trading volume of 881,621 shares on October 2, 2026. The closing price was 8.6 percent below the average analyst target, leaving the October 29 report as the next concrete test for revenue momentum, adjusted earnings and competitive positioning.